The U.S. Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee voted in favor of broadening access to six out of seven peptide substances to be used in state-licensed compounding pharmacies this past July 23–24.
Committee members determined the peptides BPC-157 for inflammation, KPV and TB-500 for wound healing, MOTS-c for obesity, Epitalon for insomnia, and Semax for cerebral ischemia, be added to an approved list of ingredients that specialty pharmacies can use to make custom medications.
Related: FDA Raises Conflict of Interest Questions on Peptide Advisory Panel
Emideltide (Delta Sleep-Inducing Peptide or DSIP), which is good for chronic insomnia, narcolepsy, and opioid withdrawal, was the one peptide the panel rejected, although the FDA will still make a final decision on the recommendations.
The panel’s decision comes amid rapidly growing consumer interest in peptide therapies for applications ranging from tissue repair and recovery to skin rejuvenation and longevity. As demand has expanded, so too have questions surrounding clinical evidence, manufacturing standards, patient safety and regulatory oversight.
Unlike FDA-approved drugs, compounded peptide therapies are prepared by licensed compounding pharmacies under specific circumstances, making the committee's recommendations particularly significant for physicians, pharmacists and patients alike.
MedEsthetics talked to New York City Board-Certified Dermatologist and Co-Founder of Mino Peptides, Dr. Amy Lewis, as well as Board-Certified Facial Plastic Surgeon in Chicago and NYC, Dr. Anil Shah, to bring more context to BPC-157 peptide specifically and to bring context to the big-picture implications.
What the FDA Committee’s BPC-157 Vote Mean?
Dr. Amy Lewis:
The committee’s vote is advisory only and is a recommendation to the FDA. It represents the opinion of an independent expert panel that reviewed the available scientific data and the current climate regarding BPC-157. The recommendation now goes to the FDA, which will make the final regulatory decision. If the FDA ultimately accepts the panel’s endorsement , BPC-157 would be eligible for compounding by licensed 503A pharmacies when prescribed for an individual patient by a licensed healthcare provider, subject to all applicable federal and state laws.
This would provide a clearer regulatory pathway for prescribing compounded BPC-157 through traditional and verified compounding pharmacies. For patients, it would improve access to peptides prepared under established pharmaceutical grade quality rather than relying on unregulated sources.
Allowing the peptides to be compounded, Kennedy has argued, “would move people away from the gray market and toward safer products.” One panelist said he voted yes for BPC-157 “for patient safety, you know, the greater good and medical freedom.” Another said his yes vote for BPC-157 was “to put this decision back into the hands of the patient, the physician and the pharmacist.”
Is this a turning point or just one step in a longer process?
Dr. Anil Shah:
I think it’s both. It’s the first major signal that the FDA is willing to seriously evaluate peptides through a regulatory pathway instead of leaving them in a gray market. That’s significant.
At the same time, we still need FDA action, better manufacturing standards, and stronger human clinical trials. Peptides represent a huge paradigm shift in the way we treat patients. They are powerful tools that the FDA wants more information on as you can dramatically potentially improve health, yet at the same time needs more data to ensure it’s going to be safe for patients.
What should physicians expect next?
Dr. Anil Shah:
For now, patience. The FDA still has to make its decision. If adopted, physicians will likely see a more structured pathway for compounding, but this won’t happen overnight. More reliable companies based in the United States are here to help. Serve the needs for both physicians and patients.
Where does BPC-157 show the most promise?
Dr. Anil Shah:
The strongest scientific rationale is for soft tissue healing—tendons, ligaments, muscle, and possibly wound healing. The animal data are impressive, and the proposed mechanisms make biologic sense. Anecdotes are equally impressive in humans and the saying where there’s smoke there’s fire may apply here. Equally impressive is that the theoretical side effects are limited and anecdotes report a well tolerated peptide.
It’s also not surprising, that the G.I. system, and disorders like inflammation, chron’s, and other diseases are where BPC-157 also shines. BPC-157 comes from the G.I. tract and is designed to protect us there.
There’s a whole host of other areas, including healing from surgery, faster, muscle repair, and even bone healing. There’s some talk about even using this after heart attacks..
How should physicians discuss this with patients?
Dr. Anil Shah:
As with any newer therapy, caution should apply. Trusted sources from well known peptide providers such as Mino Peptides can be considered. The data is going to come in rather fast and patients as well as physicians will be excited to see which therapies are available for specific conditions.
If access expands, what safeguards should clinicians have?
Dr. Anil Shah:
First, know exactly what you’re giving your patient. Product quality is everything. Your source of product is critical to your safety and for efficacy.
Use reputable compounding pharmacies, obtain informed consent, have clear treatment goals, document outcomes, and follow patients closely. Like any new therapy, it should be incorporated thoughtfully, not as a trend. The better peptide companies like Mino Peptides have physician oversight boards and develop protocols and focus on patient safety.
What quality standards matter most?
Dr. Anil Shah:
Purity, potency, sterility, and transparency.
The biggest concern with peptides has never just been the molecule—it’s whether the vial actually contains what the label says. Better quality control is essential if these therapies are going to earn physician and patient trust. Sterility is a demanding process and products sourced within the USA have the strictest of standards. The Mino platform uniquely combines three essential elements: (1) FDA-licensed manufacturing facility with 503A and 503B licenses, (2) U.S.-sourced and manufactured compounds, and (3) physician-driven oversight with ongoing patient monitoring.
Mino set out to create a platform that ensures peptides are safe, effective, and the real thing, with physician oversight.
How can patients distinguish physician-guided peptide therapy from the online gray market?
Dr. Amy Lewis:
This distinction is becoming increasingly important. Physician-guided peptide therapy involves:
- Physician oversight with comprehensive medical evaluation, including discussion of potential risks, benefits, and alternatives.
- Ongoing monitoring and follow up .
- Quality-controlled pharmacy preparation
- Better patient safety
- Reduced reliance on unregulated products
As with any newer therapy, caution should apply. As the field of peptide therapeutics advances, it's important for both patients and physicians to rely on trusted, reputable sources, such as Mino Peptides. New research is expected to emerge quickly, and with it will come growing excitement about the potential role of peptide therapies for a wide range of specific conditions.
Beyond injury recovery, are there potential applications in regenerative medicine and aesthetics?
Dr. Amy Lewis:
BPC-157 is most commonly used for tendon, ligament, and muscle healing. However, there is growing interest in its broader regenerative potential. Pre-clinical research has explored possible roles in wound healing, soft tissue repair and reduction of inflammation. Formation of new blood vessels (angiogenesis) and healing in the gastrointestinal tract for gut health are also being discussed and evaluated.
In the regenerative arena, these biological effects could hopefully translate into improved healing after procedures, scar management, or tissue regeneration. Despite promising anecdotal reports ,
these applications are still investigational. High-quality human clinical trials are still needed before widespread use and support can be recommended.
Will this increase interest in other peptides?
Dr. Amy Lewis:
Almost certainly. It is getting a lot of attention just from the recent FDA Committee meeting. The awareness is increasing and so will the questions and interest from patients, and the medical community. It would be great if this media attention encouraged additional research into other peptides with potential reparative or therapeutic applications.
Does this signal a broader regulatory shift?
Dr. Amy Lewis:
The committee’s recommendation may indicate a willingness to evaluate peptides individually for their possible merits instead of vetoing the entire class. They also are giving credence and weight to the easy availability of sub par peptides on the gray market along with the increasing demand to use them.
This is not a blanket acceptance of peptides. Each peptide has its unique pharmacology, safety data, and mechanism of action. I believe future FDA decisionswill continue to evaluate each peptide for its potential as an approved compound agent. Once the FDA accepts some peptides , I would expect others to follow more easily through this process.
When incorporating peptide therapies into patient care, physicians should work with reputable compounding pharmacies, obtain informed consent, establish clear treatment goals, carefully document outcomes, and monitor patients closely. Like any emerging therapy, peptides should be adopted thoughtfully, guided by clinical judgment, not by trends.
Companies such as Mino Peptides are helping establish a higher standard by combining physician oversight with stringent manufacturing practices. The Mino platform brings together three key elements: a licensed manufacturing facility with both 503A and 503B capabilities, U.S.-sourced pharmaceutical-grade compounds, and physician-driven protocols with ongoing patient monitoring. The goal is to ensure peptide therapies are authentic, safe, effective, and delivered within a framework of responsible medical oversight.
